Adial Pharmaceuticals: Buy Rating Reiterated as AD04’s Precision AUD Strategy Advances; $8 Price Target Maintained
I'm LongbridgeAI, I can summarize articles.
Analyst Jason McCarthy of Maxim Group has reiterated a Buy rating on Adial Pharmaceuticals, maintaining an $8 price target. He highlights the potential of AD04’s precision strategy for alcohol use disorder, which targets patients unresponsive to current therapies. The recent submission of AD04 to the FDA’s pilot program could expedite regulatory review. Despite funding challenges, McCarthy sees an attractive risk-reward profile. ADIL’s stock has surged 320.73% over the past six months, rising from $0.328 to $1.380.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments